Fluoroquinolone exposure in children linked to peripheral neuropathy, sleep disorder

14 hours ago
Fluoroquinolone exposure in children linked to peripheral neuropathy, sleep disorder

Children exposed to fluoroquinolones are more likely to have peripheral neuropathy and sleep disorder than those exposed to macrolide, according to a retrospective study.

Researchers used data from the TriNetX platform to compare the risks of musculoskeletal and neurological disorders following first exposure to fluoroquinolone vs macrolide in children. They established two cohorts, one for musculoskeletal outcome evaluation and the other for neurological outcome evaluation.

The primary musculoskeletal outcome was disorders of tendon or synovium (eg, tendinopathy, tenosynovitis), and the secondary musculoskeletal outcomes included arthralgia or arthropathy, chondropathies (ie, cartilage disorder), ligament disorder, traumatic Achilles tendon injury, spontaneous tendon rupture, and aortic aneurysm or dissection. The primary neurological outcome was peripheral neuropathy or nerve root disorder, and the secondary neurological outcomes included encephalopathy, seizure, myasthenia gravis, psychosis or delirium, sleep disorder, and extrapyramidal movement disorder.

A total of 423,880, 380,504 and 194,220 children aged <5, 5–11, and 12–17 years were matched from the fluoroquinolone and macrolide groups for the musculoskeletal cohort, and 433,746, 366,281 and 218,887 children aged <5, 5–11, and 12–17 years were matched from each group for the neurological cohort, respectively.

Findings for the musculoskeletal outcomes did not significantly differ between the fluoroquinolone and macrolide groups. For the neurological outcomes, the fluoroquinolone vs the macrolide group had greater odds of peripheral neuropathy (<5 years: odds ratio [OR], 2.22; 5–11 years: OR, 1.57; 12–17 years: OR, 1.52; p<0.001 for all) and sleep disorder (<5 years: OR, 1.34; 5–11 years: OR, 2.18; 12–17 years: OR, 1.23; p<0.001 for all).

Int J Infect Dis 2026;doi:10.1016/j.ijid.2026.109234